Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Antibiotic resistance threats in the United States, 2013.(Available at:) (Accessed October 24, 2018)
- Gram-negative antibiotic resistance: there is a price to pay.Crit Care. 2008; 12: S4
- Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options.Microb Drug Resist. 2016; 22: 412-431
- Impact of multidrug-resistant pseudomonas aeruginosa bacteremia on patient outcomes.Antimicrob Agents Chemother. 2010; 54: 3717-3722
- Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria.Antimicrob Agents Chemother. 2010; 54: 109-115
- The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.Chest. 2000; 118: 146-155
- Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.Chest. 1999; 115: 462-474
- The continuing plague of extended-spectrum beta-lactamase-producing enterobacteriaceae infections.Infect Dis Clin North Am. 2016; 30: 347-375
- Resistance in gram-negative bacteria: enterobacteriaceae.Am J Med. 2006; 119 ([discussion: S62–70]): S20-S28
- Mechanisms of antimicrobial resistance in gram-negative bacilli.Ann Intensive Care. 2015; 5: 61
- Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY antimicrobial surveillance program (2010).Antimicrob Agents Chemother. 2013; 57: 3012-3020
- Contemporary diversity of β-lactamases among enterobacteriaceae in the nine U.S. Census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.Antimicrob Agents Chemother. 2014; 58: 833-838
- Global spread of carbapenemase-producing enterobacteriaceae.Emerg Infect Dis. 2011; 17: 1791-1798
- Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant gram-negative infections.Crit Care. 2010; 14: 224
- Updated functional classification of β-lactamases.Antimicrob Agents Chemother. 2010; 54: 969-976
- Beta-lactamase inhibitors from laboratory to clinic.Clin Microbiol Rev. 1988; 1: 109-123
- The penicillins.Mayo Clin Proc. 1999; 74: 290-307
- Three decades of beta-lactamase inhibitors.Clin Microbiol Rev. 2010; 23: 160-201
- A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.Int J Antimicrob Agents. 2015; 46: 483-493
- New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world.Antimicrob Agents Chemother. 2014; 58: 1835-1846
- Novel beta-lactamase inhibitors: unlocking their potential in therapy.Drugs. 2017; 77: 615-628
- WCK 5222 (Cefepime-Zidebactam) antimicrobial activity against clinical isolates of gram-negative bacteria collected worldwide in 2015.Antimicrob Agents Chemother. 2017; 61 ([pii:e00072-17])
- Potent β-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates.Antimicrob Agents Chemother. 2017; 61 ([pii:e01238-17])
- β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.Clin Infect Dis. 2012; 54: 167-174
- Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.Antimicrob Resist Infect Control. 2015; 4: 14
- Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia.Clin Infect Dis. 2015; 60: 1319-1325
- A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing enterobacteriaceae.Antimicrob Agents Chemother. 2016; 60: 4159-4169
- Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing enterobacteriaceae.Infect Control Hosp Epidemiol. 2015; 36: 981-985
- Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae.PLoS One. 2016; 11: e0153696
- Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial.JAMA. 2018; 320: 984-994
- First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate.Antimicrob Agents Chemother. 2015; 59: 6605-6607
- Emergence of ceftazidime-avibactam resistance due to Plasmid-Borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections.Antimicrob Agents Chemother. 2017; 61 ([pii:e02097-16])
- Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates.Antimicrob Agents Chemother. 2018; 62 ([pii:e02101-17])
- Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratio.Antimicrob Agents Chemother. 1995; 39: 2591-2592
- Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.Eur J Clin Microbiol Infect Dis. 1993; 12: 356-362
- Optimal piperacillin-tazobactam dosing strategies against extended-spectrum-β-lactamase-producing enterobacteriaceae.Antimicrob Agents Chemother. 2019; 63 ([pii:e01906-18])
- A novel framework to compare the effectiveness of beta-lactamase inhibitors against extended-spectrum beta-lactamase-producing Enterobacteriaceae.Clin Microbiol Infect. 2019; ([Epub ahead of print])
- Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model.Antimicrob Agents Chemother. 2016; 60: 2075-2080
- Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors.Antimicrob Agents Chemother. 2012; 56: 2237-2240
Article info
Publication history
Published online: July 06, 2019
Footnotes
Disclosures: V.H. Tam has received honorarium from Merck. The other authors have nothing to disclose.
Funding: V.H. Tam is supported by the National Institutes of Health (R01AI140287-01).
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
